Novalgin and Xerophthalmia - a phase IV clinical study of FDA data

Summary:

We study 10,135 people who take Novalgin or have Xerophthalmia. No report of Xerophthalmia is found in people who take Novalgin.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 30, 2023

No report is found.

What is Novalgin?

Novalgin has active ingredients of metamizole. It is often used in pain. eHealthMe is studying from 8,699 Novalgin users for its effectiveness, alternative drugs and more.

What is Xerophthalmia?

Xerophthalmia (eye fails to produce tears) is found to be associated with 900 drugs and 633 conditions by eHealthMe.

Do you take Novalgin and have Xerophthalmia?

Check whether Xerophthalmia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Xerophthalmia and when was it recovered:

Xerophthalmia in Novalgin

Expand to all the drugs that have ingredients of metamizole:

Xerophthalmia and drugs with ingredients of metamizole

Alternative drugs to, pros and cons of Novalgin:

Novalgin (8,699 reports)

Xerophthalmia treatments and more:

Xerophthalmia (1,436 reports)

COVID vaccines that are related to Xerophthalmia:

All the drugs that are associated with Xerophthalmia:

Xerophthalmia

All the conditions that are associated with Xerophthalmia:

Xerophthalmia

How the study uses the data?

The study uses data from the FDA. It is based on metamizole (the active ingredients of Novalgin) and Novalgin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.